Navigation Links
Interdisciplinary Convergent Approach May Represent Future for Treatment of Atrial Fibrillation
Date:9/21/2010

MORRISVILLE, N.C., Sept. 21 /PRNewswire/ -- During the recent Atrial Fibrillation Session of the Techno College at the European Association of Cardiac Thoracic Surgeons in Geneva, Switzerland, Professor Borut Gersak, Head of Cardiac Surgery from University Medical Center in Ljubljana, Slovenia challenged his audience of more than 1,000 medical professionals to think differently about existing atrial fibrillation surgical approaches.  He called for the cardiac surgeons in attendance to encourage cardiologists to refer atrial fibrillation patients for stand-alone, interdisciplinary hybrid procedures that are significantly less invasive, yet allow for a more complete treatment of the condition and improved results.

Professor Gersak has been instrumental in developing the Convergent Procedure, a completely closed-chest surgical technique that is designed to treat all types of atrial fibrillation, the most common cardiac arrhythmia (abnormal heartbeat) affecting millions of people worldwide.  

The Convergent Procedure is a combined epicardial-endocardial ablation approach. A cardiac surgeon initially creates a comprehensive bi-atrial lesion pattern through a 2.5cm abdominal incision, without chest incisions, ports, or lung deflation. The surgeon utilizes the nContact coagulation device during epicardial ablation to create continuous, linear lesions on a beating heart. Within the same setting, an electrophysiologist will then perform endocardial ablation to complete the lesion pattern and utilize mapping and diagnostics to ensure procedure endpoints are achieved.  

"Cardiologists don't accept surgical ablation procedures as 'minimally invasive' if they require multiple thoracic incisions and lung deflation.  As such, procedures for treating atrial fibrillation must eliminate invasive chest incisions while allowing surgeons to have direct visualization of the heart and their instruments through endoscopes," stated Professor Gersak. "This subthoracic total endoscopic 'subtle' approach to surgery is the key to adoption of the Convergent Procedure, which provides a complete interdisciplinary approach to address the tougher atrial fibrillation patient populations with improved procedure times, less patient discomfort, and quicker recovery."

At the Techno College Session, cardiac surgical leaders echoed the call for improved technologies that enable less invasive surgical approaches and precise diagnostic endpoints to predict results for atrial fibrillation procedures.  

Professor Gerhard Wimmer Greinecker, Chief of Cardiac Surgery at the Heart and Vascular Center in Bad Bevensen, Germany, who chaired the atrial fibrillation session, joined Professor Gersak in support of "subtle surgery" for treating atrial fibrillation.  "Techniques such as the Convergent Procedure are the future of atrial fibrillation treatment as it leaves the thoracic cavity and lungs undisturbed, while enabling the cardiac surgeon to have visibility and access to the heart. This will be an important advantage in the minds of cardiologists and patients, as the approach is thought of simply as a 'procedure' rather than surgery. Demand for 'subtle surgical approaches' will continue to drive future innovation and adoption within the atrial fibrillation market."

About nContact Surgical, Inc.nContact is a medical device company founded in 2005 with a mission to develop devices for the endoscopic treatment of arrhythmias, including atrial fibrillation (AF).  The Numeris® Coagulation System with VisiTrax® is based on the unique integration of suction, perfusion, and RF energy to ensure the creation of visible, non-conductive, continuous, bi-atrial lesions on the epicardium of a beating heart.

To date, the Numeris® Coagulation System with VisiTrax® is indicated for endoscopic coagulation of cardiac tissue in the United States.  nContact has initiated IDE clinical studies for the treatment of AF in both open and closed chest procedures.  The Numeris Coagulation System with VisiTrax has CE Mark approval in Europe for the coagulation of cardiac tissue for the treatment of AF and atrial flutter.Media ContactsnContact Surgical. Inc.Edgar Rey

1001 Aviation Parkway, Ste 400nContact Surgical

Morrisville, NC  27560 USAT (404) 285-0466

T (919) 466-9810erey@ncontactsurgical.com

F (919) 466-9811Kimberly Muscara/Jason Rando

www.ncontactsurgical.comThe Ruth GroupT (646) 536-7011/7025kmuscara@theruthgroup.com
'/>"/>

SOURCE nContact Surgical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. nContact Announces Initiation of Clinical Trials for the Treatment of Paroxysmal Atrial Fibrillation Utilizing New Convergent Ablation Procedure
2. Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
3. ERT Launches Centralized Cardiac Safety 2.0: A Revolutionary New Approach to ECG Management in Clinical Trials
4. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
5. Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
6. Tevas Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment
7. A Unique Endoluminal Approach for the Treatment of Morbid Obesity Selected for Presentation at the 2009 American College of Surgeons Clinical Congress
8. Heart Failure Society of America 13th Annual Scientific Meeting to Focus on a Bench-To-Bedside Approach
9. Four Studies Published in The Lancet Show roflumilast (Daxas(R)), a New Oral Approach to COPD, Improves Lung Function and Reduces Exacerbations
10. MJFFs Rapid Response Innovation Awards Hit Mid-2009 With Over $1 Million Funded in High-Risk/High-Reward Approaches to Parkinsons Disease
11. Taking a Hard-Line Approach to Cardiovascular Risks in the Diabetes Patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016  Sangamo BioSciences, ... therapeutic genome editing, announced that the U.S. Food ... Investigational New Drug (IND) application for SB-318, a ... therapy for Mucopolysaccharidosis Type I (MPS I). The ... Sangamo to initiate a Phase 1/2 clinical study ...
(Date:2/8/2016)... February 8, 2016 ... published by Allied Market Research titled, "World ... Forecasts, 2014-2020", estimates the world synthetic biology market ... and sequencing technology segment would continue to lead ... tools segment, collectively, held around half of the ...
(Date:2/8/2016)... , 8. Februar 2016  LivaNova, ... heute eine Infografik mit dem Titel „Epilepsy ... Welt), mit der der Krankheit gegenüber ein ... dazu ermutigen soll, Medikamentenresistenz bei Epilepsie auf ... allgemeinen Diskussion zu machen. Mithilfe der neuen ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... ... FileHold's document management software has been implemented by DocuSyst ... for FileHold software that is pay per user subscription-based and also does on-premise ... web services API. DocuSyst also advises clients on fully functioning back up technologies ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... TopConsumerReviews.com recently ... in Mole removal products. , Moles are derived from a cluster of melanin when ... all the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... NV (PRWEB) , ... February 08, 2016 , ... Guruji ... February 9th, 10th and 11th, 2016 in honor of his birthday on February 10th. ... true happiness. Mahendra Trivedi is known by over 250,000 people from over 40 ...
(Date:2/8/2016)... ... February 08, 2016 , ... According to research by the ... dental technicians to be certified or obtain continuing education. To increase patient awareness ... In Your Mouth?” campaign to inform dentists and patients about the possible lack ...
Breaking Medicine News(10 mins):